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Abstract
Toxicity and chemoresistance are two major issues to hamper the success of current standard tumor chemotherapy.
Combined therapy of agents with different mechanisms of action is a feasible and effective means to minimize the
side effects and avoid the resistance to chemotherapeutic drugs while improving the antitumor effects. As the most
essential tumor suppressor, p53 or its pathway has been an attractive target to develop a new type of molecule-
targeting anticancer therapy. Recently, we identified a small molecule, Inauhzin (INZ), which can specifically activate
p53 by inducing its deacetylation. In this study, we tested if combination with INZ could sensitize tumor cells to the
current chemotherapeutic drugs, cisplatin (CIS) and doxorubicin (DOX).We found that compared with any single treat-
ment, combination of lower doses of INZ and CIS or DOX significantly promoted apoptosis and cell growth inhibition
in human non–small lung cancer and colon cancer cell lines in a p53-dependent fashion. This cooperative effect
between INZ and CIS on tumor suppression was also confirmed in a xenograft tumor model. Therefore, this study
suggests that specifically targeting the p53 pathway could enhance the sensitivity of cancer cells to chemotherapeutic
agents and markedly reduce the doses of the chemotherapy, possibly decreasing its adverse side effects.
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Introduction
The modern chemotherapy of cancers, which mainly refers to geno-
toxic/cytotoxic drugs [1], started around 1940s and has developed
into several types, including alkylating agents, anthracyclines, plant
alkaloids, topoisomerase inhibitors, and antimetabolites. Most of the
above chemotherapeutic drugs inhibit tumor growth by causing DNA
damages, arresting DNA replication, and cell division. As the repre-
sentatives of alkylating agents and anthracyclines, respectively, cisplatin
(CIS) and doxorubicin (DOX) are among the most potent drugs to
fight against many kinds of hematologic malignancies and solid tumors
[2,3]. Unfortunately, the dosage and treatment duration of these drugs,
which are essential for maximizing their antitumor effects, are often
limited due to severe toxicities to normal tissues, such as CIS caused
nephrotoxicity and DOX caused cardiomyopathy [3–8]. These detri-
mental effects are usually cumulative, dose-dependent, and irreversible
[5,8]. Besides toxicity, chemoresistance is another major obstacle for
effective cancer chemotherapy [9]. This can result from spontaneous
mutations occurring at the rate of 1 of 105 cells and be obtained in-
evitably with cell proliferation. However, resistance to two drugs occurs
much less frequently (fewer than 1 in 1010 cells) [1]. Therefore, combined
therapy using agents with different mechanisms of action and resistance
has become an intriguing and promising strategy to overcome side
effects and drug resistance as well as to obtain synergistic efficiency [1].
New strategies targeting aberrant pathways, dysregulated signaling
molecules in tumors, and tumor-specific antigens have been developed
during the past decade [1]. The tumor suppressor p53 is essentially
important for preventing mammalian cells from undergoing neoplasia
and tumorigenesis, primarily due to its ability to activate the transcription
of numerous genes and some miRNA responsible for executing p53-
dependent apoptosis, autophagy, senescence, and DNA repair as well
as suppression of cell proliferation, growth, migration, and angiogenesis
[10–12]. About half of human tumors contain a mutation or deletion of
the TP53 gene [13–15], and the tumors retaining wild-type p53 usually
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have other aberrations in their p53 pathway, such as amplified expres-
sion of MDM2 and/or MDMX [16]. MDM2 and MDMX are two
physiological repressors of p53, which inactivate the latter by directly
inhibiting its transcriptional activity and mediating its ubiquitination
in a feedback fashion, as they are also the transcriptional targets of
p53 [17–24]. On account of the importance of the p53-MDM2/
MDMX pathway in the initiation and development of wild-type p53-
containing tumors, intensive studies over the past decade have been
aiming to identify small molecules that could specifically target individ-
ual protein molecules of this pathway for developing a better molecule-
targeting anticancer therapy [25]. Several small molecules or peptides
have been reported to activate p53 by either blocking its binding to
MDM2 [26–28], inhibiting MDM2 E3 ubiquitin ligase activity [29],
or inhibitingMDMX-p53 binding [30]. Activating p53 by targeting its
deacetylase(s) is another new strategy. p53 acetylation by p300/CREB-
binding protein (CBP) and ubiquitination by MDM2 are mutually
exclusive [31–35], so increased acetylation could attenuate, yet increased
deacetylation could facilitate, MDM2-mediated p53 ubiquitination
and degradation [32,34,35]. On the basis of the high expression level
of SIRT1, an enzyme to catalyze deacetylation of p53, in a number of
human cancers [36–38], several inhibitors of SIRT1 [39], including
Inauhzin (INZ) by our group [16], were identified to stop MDM2-
mediated p53 degradation and induce p53 activation. Therefore, indi-
rectly interrupting theMDM2-p53 negative feedback loop by inhibiting
SIRT1 activity to enhance p53 acetylation could serve as an alternative
strategy for the development of anticancer therapy.
Activation of the p53 signaling pathway is one of the central mecha-
nisms for most of the genotoxic drugs to suppress tumor growth, while
silence of p53 can lead to chemoresistance [40–43]. Restoring and
maximizing p53 activity in tumor cells through combination of various
means could be a favorable strategy to enhance the sensitivity and reduce
the toxicity of chemotherapy. INZ, as a specific activator of the p53
pathway, bypassing DNA damage with retaining antitumor activity
and exerting a minimal effect on the cell viability of normal human
cells [16], was hypothesized to present an advantage to increase p53
activity and enhance tumor suppression, meanwhile lowering the
toxicity to normal tissues and drug resistance by combination with
lower dose of chemotherapeutic drugs. In our previous study [44],
we demonstrated the synergistic effects of combining INZ and
Nutlin-3, an inhibitor targeting the MDM2-p53 interaction [26], on
p53 activation and tumor suppression. Here, we further tested the
combined antitumor effects of INZ and current first-line chemothera-
peutic drugs, CIS and DOX, using cell-based assays and a xenograft
tumor model system. As a result, we found that the combination of
two compounds at much lower doses synergistically activates p53
and induces the proapoptotic activity in human lung and colon cancer
cell lines. We also observed the enhanced growth suppression of xeno-
grafted lung cancer with combination of INZ and CIS at lower doses.
Therefore, this study suggests that INZ, as a new-type non-genotoxic
antitumor drug candidate, could serve as a potent component of the
combined therapy to improve the antitumor effects, combat the drug
resistance, and reduce the side effects of chemotherapeutic drugs.
Materials and Methods
Chemicals and Antibodies
INZ was purchased from ChemDiv (San Diego, CA) or ChemBridge
(San Diego, CA) and dissolved with DMSO to a concentration of
50 mM and stored at −20°C. CIS and DOX were purchased from
Sigma (St Louis, MO) and dissolved with ddH2O to a concentration
of 10 mM and stored at −20°C. Cell Counting Kit was purchased
from Dojindo Molecular Technologies, Inc (Gaithersburg, MD). Fluo-
rescein In Situ Apoptosis Detection Kit was from Roche (Indianapolis,
IN). Antibodies for Western blot (WB) included rabbit polyclonal
anti-p53 (FL-393; Santa Cruz Biotechnology, Dallas, TX), rabbit
polyclonal anti-p21 (M19; Santa Cruz Biotechnology), mouse mono-
clonal anti-p21 (CP74; NeoMarkers, Fremont, CA), mouse monoclonal
anti-p21 (F-5; Santa Cruz Biotechnology), rabbit polyclonal anti-
cleaved poly (ADP-ribose) polymerase (PARP) (9542 Cell Signaling
Technology, Danvers, MA), and mouse anti–β-actin (Santa Cruz
Biotechnology). Mouse monoclonal anti-5-bromo-2′-deoxyuridine
(BrdU) antibodies (IIB5; Santa Cruz Biotechnology) were used for
immunofluorescence staining.
Cell Culture
Human non–small cell lung carcinoma wild-type p53-containing
H460 and A549, human non–small cell lung carcinoma p53-null
H1299, human colon cancer HCT116 (p53+/+ and p53−/−), and
normal human fibroblast cell line NHF-1 were maintained in
Dulbecco’s modified Eagle’s medium (Gibco BRL, Carlsbad, CA)
supplemented with 10% FBS and Penicillin-Streptomycin antibiotic
mixture (10 ml/l; Gibco BRL) at 37°C in an incubator containing
humidified air with 5% CO2.
WB Analysis
H460, A549, H1299, and HCT116 cells cultured in six-well
culture plates were grown to 80% confluence and then treated with
various concentrations of INZ together with or without CIS or DOX
for indicated time periods. After being washed with ice-cold phosphate-
buffered saline (PBS) three times, cells were lysed with 70 μl of ice-cold
lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 8.0),
5 mM EDTA, 0.5% NP-40, 1 mM DTT, 0.2 mM PMSF, 0.3 μM
aprotinin, 130 μM bestatin, 1 μM leupeptin, and 1 μg/ml pepstatin A.
Tumor tissues from the control and treatment groups saved in liquid
nitrogen were rinsed in precooled PBS, minced, and homogenized on
ice with a Dounce homogenizer in RIPA lysis buffer [150 mM NaCl,
1.0%Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 50 mM Tris (pH 7.5), 1 mM DTT, 0.2 mM PMSF, 0.3 μM
aprotinin, 130 μMbestatin, 1 μM leupeptin, and 1 μg/ml pepstatin A].
After incubation at 4°C for 30 minutes, cell or tumor tissue lysates
were obtained by centrifugation at 18,000g at 4°C for 15 minutes, and
the concentration of total protein was determined by the Bradford
method. Equal amounts (50 μg per lane) of proteins obtained as de-
scribed above were loaded to each lane and ran in a sodium dodecyl
sulfate–polyacrylamide gel electrophoresis gel and transferred onto a
nitrocellulose membrane (Bio-Rad, Hercules, CA) using a semidry
transfer apparatus (Bio-Rad). After blocking in 5% nonfat dry milk
in 1× TBS containing 0.1% Tween 20 (TBST) at room temperature
for 1 hour, membranes were incubated with primary antibodies in the
blocking buffer at 4°C overnight, followed by three washes in TBST
and incubation with secondary HRP-conjugated antibody (Bio-Rad)
at room temperature for 1 hour. After three washes in TBST, blots were
detected with SuperSignal West Pico chemiluminescent substrate
(Pierce Biotechnology Inc, Rockford, IL) and developed using Kodak
Biomax film (PerkinElmer, Norwalk, CT). All blots were normalized
against β-actin as a loading control.
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Cell Viability Assay and Assessment of Combined Drug Effect
To assess cell growth, the Cell Counting Kit (Dojindo Molecular
Technologies, Inc) was used according to the manufacturer’s instruc-
tions. Briefly, cells (5000/100 μl per well) were seeded in 96-well
flat-bottom plates, incubated overnight at 37°C, then treated with
each compound individually at serial dilutions or both compounds
simultaneously at serial dilutions with fixed molar drug ratios
(INZ/CIS = 1:2 for H460 cells, INZ/CIS = 1:7 for HCT116p53+/+,
and INZ/DOX = 20:1 for H460 and HCT116p53+/+). After treatment
for 72 hours, WST-8 was added to each well at a final concentration of
10%, and the absorbance of the samples was recorded at 450 nm on
a microplate reader (Molecular Devices, Sunnyvale, CA; SpectraMax
M5e) after 3 hours of incubation at 37°C. The dose-effect curves
were generated for each treatment to estimate the individual fractional
survival ( f ).
The combination index (CI) values were calculated to determine
the combined effects of INZ and CIS or DOX, based on the dose-
effect curves obtained above, according to the following formula as
previously developed [45]:
CI = ðDÞ1 = ðDf Þ1 + ðDÞ2 = ðDf Þ2 + a ðDÞ1ðDÞ2 = ðDf Þ1ðDf Þ2:
In this formula, (D)1 and (D)2 are the concentrations of each com-
pound of combination required to produce the fraction ( f ), (Df )1
and (Df )2 are the concentrations of individuals required to produce f,
and α = 1 or 0 depending on whether the drugs are assumed to be
mutually nonexclusive or mutually exclusive, respectively. In this
method, CI < 1, =1, or >1 indicate synergism, additivity, or antag-
onism, respectively [45].
Cell Apoptosis Analysis by Flow Cytometry
Cells (1.5 × 105) were plated into six-well plates and incubated at 37°C
overnight. After treatment of INZ andCIS or DOX at the indicated con-
centrations for 48 hours, cells were harvested, fixed in 70% ice-cold etha-
nol overnight at −20°C, resuspended in propidium iodide (PI) solution
(50 μg/ml PI, 0.1 mg/ml RNase A, 0.05% Triton X-100 in PBS) for
40minutes at 37°C, then analyzed for DNA content using a flow cytom-
eter (FACSCalibur; Becton Dickinson, Franklin Lakes, NJ) and pro-
prietary software (ModFit LT; Verity Software House, Topsham, ME).
In Vivo Studies
Five-week-old female SCID mice were purchased from In vivo Thera-
peutics Core, Indiana University Simon Cancer Center (Indianapolis, IN).
Figure 1. INZ significantly enhances CIS-induced p53 level and activity in H460 and HCT116 cells. H460 (A) or HCT116p53+/+ (B) cells were
treated with INZ or/and CIS at the indicated concentrations for 18 hours and harvested for WB analysis. Fifty micrograms of proteins was
loaded to each lane, and an anti–β-actin antibody was used as a loading control. Densitometric analyses of immunoreactive bands of p53,
p21, and cleaved PARP were expressed as fold change relative to the control group from at least three independent experiments (n = 3).
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Mice were subcutaneously inoculated with 2 × 106 H460 cells in the
right flank, and tumor growth was monitored with calipers. After the
tumors became palpable, tumor-bearing mice were randomly di-
vided into four groups and intraperitoneally (i.p.) administered INZ
(dissolved in 4% DMSO, 20 mg/kg, i.p.) once per day for 21 days
as described previously [16,44], CIS (dissolved in 1% DMSO,
3 mg/kg, i.p.) once per week for 3 weeks based on previous studies
[46,47], or vehicles (4% DMSO once per day and 1% DMSO once
per week). Tumor volume was measured every other day, and frac-
tional inhibition of tumor growth was calculated on the basis of the
tumor volume. Mice were sacrificed by euthanasia and tumors were
harvested on the last day of treatment. Tumor weight was measured
and presented in histograms.
To determine the induction of p53 and apoptotic signals in vivo,
tumor homogenates were analyzed by WB as described above.
Cell proliferation in tumors was assessed by BrdU labeling and im-
munofluorescence; 200 mg/kg body weight of BrdU was administrated
to mice through i.p. injection 2 hours before the mice were sacrificed.
In situ p53 expression was detected by immunofluorescence. Apoptosis
was also determined by in situ terminal-deoxynucleoitidyl transferase-
mediated nick end labelling (TUNEL) staining, using the Fluorescein
In Situ Cell Death Detection Kit (Roche) according to the manufac-
turer’s instructions. Briefly, tumors were fixed in 4% paraformaldehyde
overnight at 4°C, embedded in paraffin, and cut into 6-μm-thick sec-
tions. Slides were boiled in fresh 10 mM sodium citrate (pH 6.0) in a
steamer for 30 minutes for antigen retrieval, cooled for 30 minutes at
room temperature, and washed with PBS (PBS, 0.1%Tween 20). After
blocked for 1 hour in blocking buffer (PBS containing 5% goat serum
and 0.3% Triton X-100), sections were incubated overnight at 4°C
in a humidity chamber with a mouse anti-BrdU monoclonal antibody
or a rabbit anti-p53 polyclonal antibody (FL393) diluted 1:100 in the
blocking buffer, followed by incubation with an Alexa Fluor 594–
conjugated or an Alexa Fluor 488–conjugated secondary antibody for
30 minutes at room temperature. Images were obtained under a fluo-
rescence microscope (Zeiss 200), and quantitative analysis was per-
formed using ImageJ software, by counting the positive cells in six
randomly chosen fields of view, with a minimum number of 1000 cells
scored for each condition.
All animal experiments were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of Labo-
ratory Animals and were approved by the Institutional Animal Care
and Use Committee at Indiana University School of Medicine.
Statistics
Data were reported as means ± SEM with N being the sample
size. Comparisons among groups were analyzed by using one-way
analysis of variance. Probability values of P < .05 were considered
statistically significant.
Figure 2. INZ significantly enhances DOX-induced p53 level and activity in H460 and HCT116 cells. H460 (A) or HCT116p53+/+ (B) cells
were treated with INZ or/and DOX at the indicated concentrations for 18 hours and harvested for WB analysis. Fifty micrograms of
proteins was loaded to each lane, and an anti–β-actin antibody was used as a loading control. Densitometric analyses of immunoreactive
bands of p53, p21, and cleaved PARP were expressed as fold change relative to the control group from three independent experiments.
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Results
INZ Enhances the Potential of CIS or DOX to Activate p53
As canonic DNA-damaging anticancer drugs, CIS and DOX have
been proven to kill cancer cells through multiple pathways [48], and
activation of the tumor suppressor p53 is one of their major mecha-
nisms to induce cell apoptosis and growth suppression in the cancers
harboring wild-type p53 [48,49]. We recently found that INZ
induces p53 by preventing the SIRT1-mediated p53 deacetylation,
further inhibiting MDM2-mediated p53 degradation [16]. To test
the hypothesis that INZ may potentiate the ability of CIS and
DOX to activate p53, we treated p53-positive or null human non–
small cell lung carcinoma cell lines H460 and H1299 with various
doses of INZ, CIS or DOX alone, or of their mixtures for 18 hours,
followed by WB analyses with the cell lysates as shown in Figures 1A,
2A, and W2A. Consistent with previous studies [16,44], INZ, CIS, or
DOX by itself induced p53 level and activity (as indicated by the level
of p21 and cleaved PARP) in a dose-dependent fashion in H460 cells
(Figure 1A). Interestingly, although either of INZ at 0.5 μM, CIS at 1,
3, and 5 μM, or DOX at 0.2 μM slightly induced p53 and its target
expression, combined treatment of INZ and CIS or DOX at the same
lower doses significantly induced the level of p53, p21, and cleaved PARP
(Figures 1A and 2A). This cooperative effect on p53 activation was also
evident and reproducible in p53-positive human colon cancer cell line
HCT116 (Figures 1B and 2B) and p53-positive human non–small cell
lung cancer cell A549 (FigureW1). By contrast, co-treatment of p53-null
cellH1299 (FigureW2A) orHCT116p53−/− (FigureW2B) with the same
combination of the compounds did not show any significant enhance-
ment on the level of p21 and cleaved PARP, compared to either of the
single treatment, suggesting a p53-dependent cooperation of the combi-
nation. Taken together, these results indicate that INZ can cooperate
with DNA-damaging reagents to activate p53 in human cancer cells.
INZ Cooperates with CIS or DOX to Inhibit p53-Dependent
Cell Growth
To translate the synergy of INZ and CIS or DOX on the p53 path-
way into cytotoxic effects and to demonstrate that the co-activation of
the p53 pathway is indeed required for their cooperative inhibition of
cancer cell growth, we carried out a set of cell survival assays by treat-
ing either H460 or HCT116p53+/+ cells with each compound indi-
vidually or two compounds simultaneously at serial dilutions in fixed
molar ratios for 72 hours, as described in Materials and Methods
section as well as in Figures 3 and 4. The molar concentration of a
Figure 3. INZ and CIS demonstrate synergistic cytotoxicity in H460 and HCT116 cells. H460 (A) and HCT116p53+/+ (B) cells were plated in
96-well plates and treated with INZ or CIS individually at serial dilutions or both simultaneously at fixed molar drug ratios (INZ/CIS = 1:2 for
H460, INZ/CIS = 1:7 for HCT116p53+/+) for 72 hours. Cell viability was determined using aWST cell growth assay. The data here represent
the mean of three independent experiments ± SEM. CI values presented indicate the interaction of INZ with CIS when the combined
treatment inhibits cell growth by 25% (IC25), 50% (IC50), or 75% (IC75), compared to the control for their individual treatment alone.
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compound required for 50% inhibition of cellular proliferation (IC50)
was determined for each compound to establish equipotency. The IC50
of INZ and CIS in H460 cells was 3 and 6 μM, respectively, indicating
that the molar ratio for INZ and CIS to produce one-fold equipotency
is 1:2, which was then maintained for the serial dilutions of two
compounds for co-treatment (Figure 3A). The survival fractions of cells
after single treatment or co-treatment with INZ and CIS were shown
by the curves in Figure 3A.
The values for CI, which indicate either synergism (less than 1) or
antagonism (greater than 1), were calculated as described in Materials
and Methods section when the co-treatment of H460 cells with INZ
and CIS reduced cellular survival by 25% (IC25), 50% (IC50), or
75% (IC75) and plotted in the right panels of Figure 3A. In line with
the results shown in Figure 1A, combination of INZ and CIS dis-
played obvious synergism in suppressing the growth of H460, as the
CI values at a range of effective doses were clearly less than 1 (Fig-
ure 3A). The interplay between INZ and CIS in HCT116p53+/+ cells
(Figure 3B), or between INZ and DOX in H460 and HCT116p53+/+
cells (Figure 4, A and B), was also assessed by employing the same
method. As shown in Figure 4, A and B, in H460 and HCT116p53+/+
cells, apparent synergy was evident in the co-treatment with INZ and
DOX, as their CI values were obviously less than 1. The CI values
for combination of INZ and CIS in HCT116p53+/+ cells were close
to but still lower than 1 (Figure 3A), suggesting the possible additive
effect between these two compounds in this cancer cell line. However,
the synergistic cell growth inhibition of INZ and CIS or DOX was not
observed in p53-null cells and normal human fibroblast cell NHF-1
(FiguresW2 andW3), suggesting that the synergistic suppression of cell
growth by combination of INZ andCIS orDOX is p53-dependent, but
not evident in normal cells. These results demonstrate that INZ and
DNA-damaging drugs can synergistically repress the growth of human
cancer cell lines in a p53-dependent manner.
INZ and CIS or DOX Synergistically Induce
p53-Dependent Apoptosis
To further address the p53-dependent synergistic antitumor effect
of INZ and DNA-damaging drugs, we detected cell apoptosis, which
is one of major mechanisms for p53 to inhibit tumor growth. The
results from Figures 1, 2, 3, 4, and W1 also showed the increased
amount of cleaved PARP, an indicator of cell apoptosis, by co-treatment
of p53-possessing H460, HCT116, and A549 cells with INZ and CIS
or DOX, suggesting that this combinational treatment might induce
p53-dependent apoptosis. We performed fluorescence-activated cell
sorter analyses (FACS) of H460 and HCT116p53+/+ cells after treat-
ment with INZ and CIS or DOX for 48 hours (Figures 5 and 6). In
this assay, the molar ratios of compounds for co-treatment were still
maintained the same as that in the cell survival assay as described above.
As shown in Figures 5A and 6A, either 2 μM CIS or 0.05 μM DOX
exerted slight effects on apoptosis in H460 cells (∼3% of apoptosis),
whereas 1 μM INZ induced approximately 6% to 7% of apoptotic
Figure 4. INZ and DOX demonstrate synergistic cytotoxicity in H460 and HCT116p53+/+ cells. H460 (A) and HCT116p53+/+ (B) cells were
plated in 96-well plates and treatedwith INZorDOX individually at serial dilutions or both simultaneously at fixedmolar drug ratios (INZ/DOX=
20:1 for H460 andHCT116p53+/+) for 72 hours. Cell viabilitywas determined using aWSTcell growth assay. The data here represent themean of
three independent experiments ± SEM. CI values presented indicate the synergy of INZ with DOX assessed as that for INZ and CIS in Figure 3.
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cells. However, combinational treatment of H460 cells with the same
dose of INZ and CIS (or DOX) significantly raised the apoptotic
rate to 14% to 18%. For HCT116p53+/+ cells, either 28 μM CIS
or 0.2 μM DOX only induced 3% to 5% of apoptosis, and 4 μM
INZ induced 6% to 7% of apoptosis; however, combined treatment
dramatically increased apoptosis to ∼24% and ∼15%, respectively
(Figures 5B and 6B). Even at lower doses of combination, additive
effect was still exhibited in HCT116p53+/+ cells (Figures 5B and
6B). Obviously, INZ sensitized these cancer cells to CIS or DOX,
synergistically promoting apoptosis. This synergy on proapoptotic
effect of these compounds was not seen in p53-null cells (as indicated
by the level of cleaved PARP in Figure W2). Taken together, these
results demonstrate that INZ and DNA-damaging drugs can synergis-
tically suppress cell survival by inducing p53-dependent apoptosis.
INZ and CIS Cooperatively Suppress Xenograft
Tumor Growth
The above results show that combination of INZ and chemo-
therapeutic drugs is considerably effective in suppressing the growth
of wild-type p53 containing cancer cells H460 and HCT116. To
ranslate the cooperation of these compounds into biologic signifi-
cance, we further tested if INZ could also synergistically enhance
the anticancer effect of CIS by employing a xenograft tumor model
system derived fromH460 cells. Since our previous study showed that
INZ at 30 mg/kg through i.p. injection reduced the HCT116p53+/+
tumor volume by 60% to 70% [16], or at 60 mg/kg reduced the H460
tumor volume by 50% to 60% (unpublished data), here we chose
20 mg/kg INZ for the in vivo study with low dose of CIS (3 mg/kg)
as detailed in Materials and Methods section. As indicated in Figure 7,
Figure 5. INZ significantly enhances the proapoptotic effect of CIS on H460 and HCT116 cells. H460 (A) and HCT116p53+/+ (B) were
plated in 6-cm-diameter dishes and treated with INZ or/and CIS at the indicated concentrations for 48 hours. Cells were stained with PI
and subjected to flow cytometry to determine the DNA content. The apoptotic cells, identified by sub-G1 DNA content, were presented
as the M1 population. The data were expressed as means ± SEM (n = 4).
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INZ or CIS alone reduced the average tumor volume by 25% to 30%
or 45% to 50%, respectively. However, combination of the two com-
pounds at the same doses significantly decreased the final tumor size by
80% to 85%. Furthermore, the final tumor weight also decreased to
∼20% of the control by combined treatment, which displayed statisti-
cal significance compared with the other three groups (Figure 7A). This
result confirmed that INZ could indeed potentiate CIS-induced
growth suppression of H460-derived xenograft tumors in vivo. Consis-
tent with this result, the two compounds synergistically induced p53
level and activity (Figure 7, B and C ) as well as remarkably suppressed
cell proliferation and induced apoptosis (Figure 7C ). These results
demonstrate that INZ and DNA-damaging chemotherapeutic drugs,
such as CIS, can cooperatively activate p53 and suppress xenografted
tumor growth in animals as well.
Discussion
Severe side effects and drug resistance are two major obstacles to limit
the use of genotoxic agents, such as CIS and DOX, in systemic
chemotherapy. Finding novel strategies to overcome the adverse
effects and sensitize the response to existing antitumor drugs is an
urgent and arduous challenge in the field of cancer chemotherapy
and would have a significant clinical impact. In this study, we dem-
onstrate that combination of INZ with low dose of CIS or DOX can
synergize their abilities to significantly induce apoptosis and to in-
hibit growth of human wild-type p53 harboring non–small cell lung
cancer cells and colon cancer cells.
Activation of the p53 pathway has been known as one of the
central mechanisms for the DNA-damaging agents to induce cell
apoptosis and tumor inhibition [50]. Various DNA lesions, such as
CIS-caused interstrand DNA cross-linking and DOX-caused DNA
double-strand breaks, trigger the activation of ATM and ATR, fol-
lowed by phosphorylating downstream proteins related to cell growth,
proliferation, and survival, among which p53 is the prominent protein
to be phosphorylated, stabilized, and activated [51–57]. In addition,
phosphorylated ChK1/2 by ATM and ATR further phosphorylates
MDMX, leading to the binding between p-MDMX and 14-3-3, and
results in the disruption of the interaction between MDMX and p53,
Figure 6. INZ significantly enhances the proapoptotic effect of DOX on H460 and HCT116 cells. H460 (A) and HCT116p53+/+ (B) were
plated in 6-cm-diameter dishes and treated with INZ or/and DOX at the indicated concentrations for 48 hours. Apoptotic cells were
analyzed as described above in Figure 5. The data were expressed as means ± SEM (n = 4).
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causing p53 stabilization and activation [58–61]. Maximizing the
activity of p53 by concomitantly targeting different components in this
pathway should be an effective approach to impede the growth of
tumors harboring functional p53. INZ, as reported previously by our
group, is a potent nongenotoxic p53 activator by inhibiting SIRT1-
mediated deacetylation [16]. Combination of DNA-damaging agents
with INZ would not only induce the phosphorylation of p53 in
response to activation of ATM and ATR but also increase the acetyla-
tion and weaken the ubiquitination of p53 due to inactivated SIRT1.
The sum outcome of this double treatment is, therefore, the more
remarkable induction of p53 level and activity. Indeed, as expected,
in both p53-containing H460 and HCT116 cells, p53 level and
activity (indicated by the p21 level) exhibited a dramatic augment after
combined treatment with INZ and CIS or DOX, even at relatively
lower doses, compared with either of the single treatment (Figures 1,
2, and W1). Our subsequent results further proved the p53-dependent
cooperation between INZ and genotoxic drugs, particularly CIS, on
cell growth inhibition, which might be attributed to the augment of
apoptotic response, in p53 wild-type cells but not in p53-null cells (Fig-
ures 3, 4, 5, 6, and W2).
One of the most strenuous challenges for the oncologists in
current cancer chemotherapeutic practice is the cumulative and dose-
dependent toxicity to normal tissues, such as nephrotoxicity and cardio-
myopathy caused by CIS and DOX, respectively. Both CIS and DOX
have been supposed to cause side effects by some mechanisms different
from the typical DNA lesions that are primarily responsible for their
suppression on tumor growth [3,5,62,63]. For instance, CIS may
be metabolized to a reactive toxic thiol by some enzymes such as
γ-glutamyl transpeptidase whose high level in renal proximal tubular
cells sensitizes the cells to CIS toxicity and further target the mito-
chondria and endoplasmic reticulum of the proximal tubular cells
[5,64–66]. Several approaches have been developed against the tox-
icity, including application of prodrugs and derivatives [67,68],
combination with some specific protectors such as antioxidants
[69–71], and improvement of drug delivery systems [72–74]. Low-
ering drug dosage by combination with agents with different
mechanisms of action should be a simple, feasible, and effective
means to minimize the side effects of DNA-interfering drugs, while
retaining the antitumor effects. Again, our results prove that INZ
possesses this kind of capability based on its specific p53 induction
Figure 7. INZ significantly enhances CIS-induced p53 activation, apoptosis, and tumor suppression. (A) Combination of INZ and CIS
markedly suppresses the growth of xenograft tumors derived from H460 cells. Mice bearing H460 xenografts were i.p. treated with
INZ (20 mg/kg) everyday or/and CIS (3 mg/kg) once per week or vehicles for 21 days. Images of tumors isolated are presented at the
left. The tumor growth is shown by the mean tumor volumes ± SEM (middle), and the final tumor weight is shown in columns (right;
n = 6 mice per group; *P < .05). (B) WB analysis of proteins extracted from H460 tumor samples in A with antibodies as indicated on
the right. (C) Representative images of TUNEL staining, BrdU, and p53 immunostaining of xenograft tumor sections are presented.
Quantification of BrdU and TUNEL staining is expressed as mean ± SEM (n = 4 mice per group).
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in tumors and minimal side effects on normal cells and tissues [16],
as even much lower doses of CIS or INZ are required for combined
therapy to achieve a satisfactory anticancer effect on tumor xeno-
grafts with wild-type p53 (Figure 7), but the same combination
exerted little synergistic effect on normal cells (Figure W3). Even
though more studies are needed to further illuminate the low toxic-
ity of INZ in normal cells and tissues, INZ could be a promising
component for adjuvant antitumor therapy.
Another major cause of treatment failure during tumor chemo-
therapy is drug resistance, which is a complicated multifactorial event.
Taking CIS as an example again, the chemoresistance may involve
many aspects, including loss of apoptotic response [41,75], overactiva-
tion of survival signals such as phosphatidylinositol 3-kinase (PI3K)/
Akt [40,42,76–78], increased DNA repair [79–82], induction of
multidrug resistance [83,84], increased efflux, and decreased influx
of the drug [82]. A number of in vitro, in vivo, and clinical studies
support p53 as an important regulator during most of these processes
to mediate the drug sensitivity [40–42,75,76,85–95]. Activation of
prosurvival factor Akt [40,76], CBP/p300-interacting transactivator
protein CITED2 [96], which is critical for cell growth and oncogenesis
[96], oncogenic phosphatase protein PPM1D [41], or protein traffick-
ing related protein NAPA [90] renders cancer cells resistant to chemo-
therapy, while suppression of their activity sensitizes cells to CIS, which
requires the activation of wild-type p53. P53-HDAC2 complex re-
presses the expression of multidrug resistance–related protein lung
resistance–related protein (LRP) through binding to the LRP promoter,
whereas loss of p53-mediated suppression on LRP may cause the
chemoresistance in tumor cells [86]. Down-regulation of p53 in human
breast cancer cells increases the CIS resistance mediated by variant,
which is one of the factors in charge of DNA repair and telomere main-
tenance [97]. Restoration or reactivation of wild-type p53 dramatically
improved the apoptotic response and sensitivity to CIS in tumor cells
[49,85,98–100]. On the basis of these findings, it would be rational
to sensitize the chemotherapy by specifically targeting p53, with very
low possibility to induce a secondary pathway related to drug resistance.
Our study as presented here indeed demonstrates that the specific p53
inducer INZ can sensitize cancer cells, particularly the lung cancer
cell line H460 whose chemotherapy is mainly composed of CIS-based
regimen, to low dose of CIS, leading to tumor suppression in a p53-
dependent manner (Figures 3–7 and W2). Studies on chemoresistant
cancer cell lines are necessary to further address the beneficial effects of
combination with INZ and chemotherapy on drug sensitivity. Never-
theless, taken together, our current findings suggest that specifically
targeting the p53 pathway promotes the sensitivity of cancer cells to
traditional chemotherapeutic drugs, and combination of INZ with
standard chemotherapy will provide an attractive anticancer protocol
for the cancer patients with high sensitivity to side effects and refractory
drug resistance in the future.
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Figure W1. INZ significantly enhances the expression level and
activity of p53 as well as the apoptotic response induced by DOX in
A549cells in a dose-dependentmanner. Cellswere treatedwith INZor
DOX at the indicated concentrations for 18 hours and harvested for
WB analysis. Fifty micrograms of proteins was loaded in each lane,
and an anti–β-actin antibody was used to confirm equal loading.
Similar results were obtained from three separate experiments.
Figure W2. INZ does not enhance the cell apoptotic response and cytotoxicity in the presence of CIS or DOX in p53-null cells. (Left)
H1299 (A) and HCT116p53−/− (B) were treated with INZ or/and CIS/DOX at the indicated concentrations for 18 hours and harvested for
WB analysis. Fifty micrograms of protein was loaded in each lane, and an anti–β-actin antibody was used to confirm equal loading.
Similar results were obtained from three separate experiments. (Right) H1299 (A) and HCT116p53−/− (B) were plated in 96-well plates
and treated with INZ or CIS/DOX individually or both simultaneously at the indicated concentrations for 72 hours. Cell viability was
determined using the WST cell growth assay. The data shown represent the mean of three independent experiments ± SEM.
Figure W3. INZ does not enhance the cytotoxic effect of CIS or DOX on NHF-1 cells. NHF-1 cells were plated in 96-well plates and
treated with INZ or CIS/DOX individually or both simultaneously at the indicated concentrations for 72 hours. Cell viability was deter-
mined using the WST cell growth assay. The data shown represent the mean of three independent experiments ± SEM.
